tbuckley/cabot-search huggingface dataset:
Abstract 9964: Plaque Morphology, Plaque Composition and Spatial Distribution of the Sites of Potential Vulnerability of Culprit Lesions Implicated in Acute Myocardial Infarction
Authors: Guian Zheng, Yuxin Li, Takafumi Hiro, Tadateru Takayama, Yoshiharu Higuchi, Daisuke Fukamachi, Hironori Haruta, Mitsumasa Sudo, Toshihiko Nishida, Satoshi Saito, Atsushi Hirayama
Journal: Circulation (2015)

Background: The role of plaque morphology, composition, and spatial distribution in plaque rupture and coronary occlusion in patients suffering acute myocardial infarction (AMI) needs clarification. Using color-mapping iMAP intravascular ultrasound (iMAP-IVUS), we examined culprit lesions to clarify plaque morphology, plaque composition and spatial distribution of the sites of potential vulnerability. Methods: Sixty-eight culprit lesions in 64 consecutive AMI patients who underwent angiography and IVUS examinations before intervention were analyzed. Plaque morphology and composition were quantified and compared between totally occlusive (TO) (n=42) and non-TO lesions and between ruptured (n=27) and non-ruptured lesions. Results: Both the length and plaque burden (PB) of TO lesions were greater than those of non-TO lesions (54.16 ± 21.16 mm versus 40.01 ± 17.51 mm, respectively, p = 0.006; PB: 0.63 ± 0.07 versus 0.58 ± 0.08, respectively, p = 0.02). Ruptured lesions were coincident with significant vessel remodeling (vessel volume: 745.5 ± 41.3 mm3 versus 635.7 ± 33.5 mm3, p = 0.04) and plaque volume (450.0 ± 23.8 mm3 versus 387.7 ± 19.3 mm3, p = 0.046). Also, the lipidic volume was greater (57.6 ± 3.8 mm3 versus 46.9 ± 3.1 mm3, p = 0.03) and the necrotic volume (152.6 ± 12.1 mm3 versus 125.8 ± 9.8 mm3, p = 0.09) tended to be greater in ruptured lesions. Examination of the longitudinal distribution of the sites of recognized vulnerability, i.e., maximum necrotic area (maxNA), maximum PB (maxPB) and most severely narrowed (minimal luminal area, MLA) revealed that most maxNA sites and maxPB sites were proximal to MLA sites. Ruptures usually occurred very close to maxNA sites (average distance: 0.33mm, 44% were proximal to, 26% overlapped and 30% were distal to a maxNA site) and proximal to maxPB and MLA sites. Conclusion: Plaque morphology and composition play critical roles in plaque rupture and coronary occlusion. The maxNA sites are the sites most likely to rupture, and most ruptures occur proximal to maxPB sites and MLA sites.
18F-FDG PET/CT Imaging of Cauda Equina Syndrome Secondary to Leptomeningeal Metastatic Breast Cancer
Authors: Lilja B. Solnes, Mehrbod S. Javadi, Steven P. Rowe
Journal: Clinical Nuclear Medicine (2016)

Cauda equina syndrome (CES) is an uncommon entity that may be caused by a variety of conditions. It refers to dysfunction of the ventral, dorsal, sacral, and coccygeal nerve roots in the region of the filum terminale. We present a case of a 32-year-old woman with a history of BRCA1-positive metastatic breast cancer who complained of lower extremity muscle weakness increasing over a 2-week period and decreased sensation of the lower extremities accompanied by severe constipation and suspected urinary retention with overflow incontinence. The patient underwent whole-body F-FDG PET/CT and MRI of the spine with and without gadolinium-based contrast.
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
Authors: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Michael Lim, Gavin P Dunn, Hui Kong Gan, Timothy Francis Cloughesy, Jennifer Leigh Clarke, Andrew J. Park, Mary J. Macri, Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Rudolph Venhaus
Journal: Journal of Clinical Oncology (2016)

TPS2080 Background: Outcome among newly diagnosed and recurrent GBM patients remains poor, and novel therapeutic approaches are needed. Blockade of Programmed death-1 (PD-1) and PD-ligand 1 (PD-L1) has shown promising clinical benefit among solid tumors, and data implicate PD-1/PD-L1 signaling as a significant contributor to immunosuppression in GBM. Specifically, PD-1 is expressed by many GBM infiltrating lymphocytes, PD-L1 is expressed by 61-100% of GBM tumors, and loss of the PTEN tumor suppressor gene, occurring in 40-50% of GBM tumors, leads to increased transcription and expression of PD-L1. Durvalumab (DUR) is a human IgG1 mAb against PD-L1. Bevacizumab (BEV) is a mAb against VEGF, and data suggest that VEGF inhibition may enhance the antitumor benefit of immunotherapies. Methods: This ongoing Phase 2, multicenter, open-label study (NCT02336165) is designed to evaluate the clinical efficacy and safety of DUR (10 mg/kg i.v. Q2W for 12 months) in 5 cohorts of newly diagnosed and recurrent GBM patients. Eligible patients include those who are newly diagnosed with GBM with unmethylated MGMT promoter and scheduled for radiotherapy (Cohort A); BEV-naïve patients with recurrent GBM (Cohorts B, B2 and B3); and BEV-refractory patients with recurrent GBM (Cohort C). Cohort A patients receive DUR beginning with radiotherapy. Cohort B patients receive DUR as monotherapy, and Cohorts B2 and B3 receive DUR plus BEV at 10 mg/kg Q2W or 3 mg/kg Q2W, respectively. Cohort C patients receive DUR with continued BEV at 10 mg/kg Q2W. Primary endpoints are overall survival at 12 months (OS-12) (Cohort A), progression free survival at 6 months (PFS-6) (Cohorts B, B2, B3), and OS-6 (Cohort C). Secondary endpoints are safety/tolerability, median PFS/OS and overall response rate, DUR pharmacokinetics, and quality of life measures. Exploratory endpoints are neurologic function by NANO and immunocorrelative biomarkers. Enrollment as of 31Dec2015, with no DLTs reported during the 3+3 safety run-in, is: Cohort A, 5 of planned 37 patients; Cohort B, 31 of planned 30 patients (complete); Cohort C, 13 of planned 17 patients. Cohorts A and C are continuing enrollment; Cohorts B2 and B3 (n = 32 each) opened to enrollment in Dec 2015. Clinical trial information: NCT02336165.
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Authors: Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Loic Mourey, Paul N. Mainwaring, Daniel Ford, Jeremy David Shapiro, Joan Carles, Siobhan Ng, Thierry Gil, Boris Alekseev, Sergey Ivanov, Thomas Facchini, Eric Legouffe, Oleg Apolikhin, Hardev S. Pandha, Aart Beeker, Oleg Karyakin, Wendy Zhang, Mustapha Chadjaa, Johann Sebastian De Bono
Journal: Journal of Clinical Oncology (2012)

TPS4692^ Background: The phase III TROPIC study (NCT00417079) reported a significant improvement in overall survival (OS) for cabazitaxel (Cbz) + prednisone (P;CbzP) (25 mg/m 2 IV Q3W/10 mg PO QD) vs mitoxantrone (M) + P (MP) (median OS 15.1 vs 12.7 mos; HR 0.70; P &lt; 0.0001) in pts with mCRPC (also known as hormone-refractory prostate cancer) previously treated with a D-containing regimen. CbzP is approved by the FDA, EMA and other health authorities for the treatment of pts with mCRPC that has progressed after a D-containing regimen. Cbz toxicity is consistent with other taxanes; compared with M, more hematologic toxicities are reported (primarily Grade 3–4 neutropenia). Phase I/II studies identified 20 and 25 mg/m 2 as recommended doses; 25 mg/m 2 was selected for the phase III TROPIC study. As pooled data show Grade 3–4 neutropenia incidence is lower with Cbz &lt; 25 mg/m 2 (61%) vs ≥ 25 mg/m 2 (74%), it is of interest to assess if reducing the Cbz approved dose in mCRPC lessens hematologic toxicity and is non-inferior in terms of efficacy. Methods: PROSELICA (NCT01308580) is a randomized, open-label, multinational, phase III study comparing 20 mg/m 2 and 25 mg/m 2 Cbz for efficacy and tolerability. Pts with a life expectancy &gt; 6 mos, ECOG PS ≤ 2, histologically/cytologically confirmed metastatic prostate adenocarcinoma resistant to hormone therapy and previously treated with a D-containing regimen are eligible. Pts are randomized 1:1 to receive Cbz 20 mg/m² or 25 mg/m² IV Q3W + P 10 mg PO QD, treated until disease progression, unacceptable toxicity or withdrawal of consent (max 10 cycles), and stratified according to ECOG PS, measurable disease (yes/no) and region. The primary endpoint is OS (non-inferiority design). Secondary endpoints include safety, progression-free survival (PCWG2 criteria), PSA and pain progression and response, tumor response in pts with measurable disease and health-related quality of life. Cbz PK and pharmacogenomics will be assessed in pt subgroups. Planned enrollment is 1,200 pts. Study start was in May 2011; as of Jan 2012, 270 pts had been enrolled. The first DMC meeting recommended continuing the study without change.
Sunitinib therapy for metastatic melanomas with KIT aberrations.
Authors: D. R. Minor, S. O'Day, M. Kashani-Sabet, A. Daud, Z. Salman, B. Bastian
Journal: Journal of Clinical Oncology (2010)

8545 Background: Recent studies have shown that KIT gene aberrations can be found in melanomas originating from mucosal or acral sites, or skin with chronic sun-damage (CSD), and may respond to treatment with KIT inhibitors such as imatinib. We wanted to determine the predictors of response to therapy with the KITinhibitor sunitinib. Methods: We screened tumors for KIT aberrations using sequencing of exons 9, 11, 13, 17, and 18, FISH analysis, and immunohistochemistry for CD117. Patients with KIT mutations, amplification > 1.5, or CD117 staining 2+ in over 50% of cells were eligible for therapy with sunitinib 50mg/day 4 weeks on 2 off, and responses were evaluated using RECIST criteria. Results: See Table. Six patients had KIT mutations; five in exon 11 and one in exon 13. All were wild type for BRAF, NRAS, and GNAQ. Two also had KIT copy number increase determined by FISH. Three could be started on treatment. One patient with mucosal melanoma and KIT mutation exon 11 W557G had a partial response lasting for 7 months, one progressed, and one was non- evaluable. Of the 11 patients who had KIT copy number increase without mutations three were treated: one had a transient partial response lasting three months and two had progressive disease. Two patients without mutations or amplification that were CD 117 positive were treated and one had a partial response. Conclusions: At this early point in the trial, KIT mutations may indicate sensitivity to sunitinib. Primary No. of patients KIT mutation KIT amplification CD117+ Acral 16 2 4 9 Mucosal 28 3 7 7 CSD 28 1 2 7 Totals 72 6 13 23 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pfizer
Low-Dose Ionizing Radiation Modulates Expression of Gpam in Immortalized EBV Infected B Cells through miRNA Network
Authors: Yoko Tabe, Yasuhito Hatanaka, Mayumi Nakashiro, Kazumasa Sekihara, Shinichi Yamamoto, Hiromichi Matsushita, Saiko Kazuno, Michael Andreeff, Marina Konopleva, Keisuke Sasai, Takashi Miida
Journal: Blood (2015)
Self-directed tablet education session improves safety knowledge among patients undergoing phototherapy
Authors: C.L. Thomas, A.K. Kennedy, S. Choi-Lombardi, M. Sgarioto, P. Fernández Peñas
Journal: British Journal of Dermatology (2016)

Narrowband ultraviolet B radiation therapy (phototherapy) is frequently used in the management of common dermatological conditions 1-3. For safe, effective treatment, patients must understand the procedures, responsibilities and risks involved. Inadequate understanding can lead to poor compliance, adverse effects and inappropriate expectations.

This article is protected by copyright. All rights reserved.
Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study
Authors: Shitaldas J. Pamnani, Staci L. Sudenga, Raphael Viscidi, Dana E. Rollison, B. Nelson Torres, Donna J. Ingles, Martha Abrahamsen, Luisa L. Villa, Eduardo Lazcano-Ponce, Jorge Salmeron, Manuel Quiterio, Yangxin Huang, Amy Borenstein, Anna R. Giuliano
Journal: Cancer Research (2016)

Abstract Naturally induced serum antibodies against human papillomavirus (HPV) may affect risks of subsequent incident genital infections by HPV 6, 11, 16, or 18 in men. In this study, we examined the hypothesis by following 4,123 healthy men every 6 months (median follow-up time, 4.1 years). HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay. Genital HPV genotypes were detected using Roche Linear Array. Incidence proportions and 6-month persistence proportions were calculated at 6-month intervals. Kaplan–Meier curves and Cox models were used to assess genotype-specific cumulative incidence and HRs, respectively. HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respectively. Significantly higher rates of incident infections were observed for HPV 16 among baseline-seropositive men [adjusted HR, 1.37; 95% confidence interval (CI), 1.01–1.86], with similar but nonsignificant HRs for 6-month persistent infections. Risk of persistent HPV 18 infection was significantly lower among seropositive men in the unadjusted model (HR, 0.22; 95% CI, 0.06–0.91), but not in the adjusted model (HR, 0.19; 95% CI, 0.03–1.37). Incident and 6-month persistent infections for HPV 6 and 11 did not differ by baseline serostatus. Baseline serostatus among men was not associated with a reduction in subsequent incident genital HPV 6, 11, and 16 infections. However, protection against persistent HPV18 infections was observed in unadjusted models. Our research suggests a need of further studies to examine the potentially protective effects of naturally induced HPV18 antibodies in men. Cancer Res; 76(20); 6066–75. ©2016 AACR.
Genomic Analysis of Serial Chronic Lymphocytic Leukemia Samples Suggests That Epigenetic Changes, Rather Than Clonal Evolution, May Drive the Progression of This Leukemia
Authors: Emanuela M. Ghia, Erin Smith, Christopher DeBoever, Laura Z. Rassenti, Sophie Rozenzhak, Peter Shepard, Hakan Alakus, Olivier Harismendy, Christian L Barrett, Kelly A Frazer, Thomas J. Kipps
Journal: Blood (2012)
The JAK2 V617F Tyrosine Kinase Mutation in Myelofibrosis with Myeloid Metaplasia: Clinical Correlates and Prognostic Relevance in 157 Patients.
Authors: Ayalew Tefferi, Terra L. Lasho, Susan M. Schwager, David P. Steensma, Ruben A. Mesa, Chin Yang Li, Martha Wadleigh, D. Gary Gilliland
Journal: Blood (2005)
Epidermodysplasia verruciformis as a manifestation of ARTEMIS deficiency in a young adult
Authors: Azzedine Tahiat, Yousef R. Badran, Janet Chou, Brittney Cangemi, Gerard Lefranc, Zakaria-Merouane Labgaa, Salma Oussalam, Assia Kaddouri-Slimani, Ayad Belarbi, Kheira Bendissari-Bouzid, Merzak Gharnaout, Raif S. Geha, Réda Djidjik, Michel J. Massaad
Journal: Journal of Allergy and Clinical Immunology (2016)
Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Authors: Vincent Auffret, Ander Regueiro, María Del Trigo, Omar Abdul-Jawad Altisent, Francisco Campelo-Parada, Olivier Chiche, Rishi Puri, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2016)
Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).
Authors: E. Gallerani, J. Delord, P. Schoffski, I. B. Vergote, V. N. Trillet-Lenoir, M. Maur, M. G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso
Journal: Journal of Clinical Oncology (2010)

5014 Background: D is a small molecule that inhibits a urora kinases, proteins regulating mitosis implicated in tumorigenesis and overexpressed in BC and OC. Methods: In both tumor categories eligible patients (pts) were progressing after 2 prior chemotherapy lines for advanced/metastatic disease; OC pts were resistant or refractory to platinum- based therapy. We evaluated the progression-free rate at 4 months (PFR-4) in a Simon two-stage design. To proceed to the second stage, ≥4 or ≥10 pts free from progression at 4 months were required in BC and OC out of 19 and 24 evaluable pts, respectively. D (500 mg/m2) was administered IV over 24 hours every 14 days. Results: In BC, 42 pts, median age 53 [36-70] years were treated; both stages were completed; 4 pts were not evaluable for efficacy. Seven out of 38 evaluable pts were progression free at 4 months. This result cannot allow to conclude in favor of PFR-4 greater than 20%, set per protocol to define a sufficient activity. Best response was SD in 11 pts (median duration: 20 weeks). In OC, 34 pts, median age 60 [35-76] years, were treated and two withdrew their consent. Twenty-four pts were platinum resistant (50% after primary platinum based CT), and 10 pts platinum refractory (all cases except one after primary platinum based CT). Four pts were free from progression at 4 months and the study was closed after stage 1. Best response was a confirmed PR in 1 pt which lasted 17.3 weeks, and was associated with a partial metabolic response on PET and a drop in CA125 by 80% at 4 months. There were 10 pts with SD. The most frequent grade (G) 3/4 (NCI-CTCAE, version 3.0) hematological toxicity consisted of short lasting neutropenia (86%). G3 lymphocytopenia and thrombocytopenia occurred in 7 and 1 pts, respectively; G 3/4 anemia was noted in 2 pts. The most common non-hematological G3/4 drug-related events were fatigue (10 pts) and febrile neutropenia (5 pts). Diarrhea and pyrexia were noted in 2 pts each. Conclusions: The efficacy of D observed in this trial of third-line treatment of BC and platinum resistant/refractory OC at this dose and regimen did not meet the predefined boundaries of the protocol. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Nerviano Medical Sciences
Interleukin-30 Promotes Breast Cancer Growth and Progression
Authors: Irma Airoldi, Claudia Cocco, Carlo Sorrentino, Domenico Angelucci, Serena Di Meo, Lamberto Manzoli, Silvia Esposito, Domenico Ribatti, Maria Bertolotto, Laura Iezzi, Clara Natoli, Emma Di Carlo
Journal: Cancer Research (2016)

Abstract The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting the breast cancer cell viability and invasive migration. IL30 was absent in normal mammary ducts, ductules, and acini of histologically normal breast and scanty in the few stromal infiltrating leukocytes. In contrast, IL30 was expressed frequently in breast cancer specimens where it was associated with triple-negative and HER2+ molecular subtypes. In stromal leukocytes found in primary tumors or tumor-draining lymph nodes, which included mainly CD14+ monocytes, CD68+ macrophages, and CD33+/CD11b+ myeloid cells, IL30 levels increased with disease stage and correlated with recurrence. A negative correlation was determined between IL30 expression by nodal stromal leukocytes and overall survival. In vitro studies showed that human recombinant IL30 upregulated expression of a pro-oncogenic program, including especially IL6 in both triple-negative and HER2+ breast cancer cells. In triple-negative breast cancer cells, IL30 boosted a broader program of proliferation, invasive migration, and an inflammatory milieu associated with KISS1-dependent metastasis. Silencing of STAT1/STAT3 signaling hindered the regulation of the primary growth and progression factors in breast cancer cells. IL30 administration in vivo fostered the growth of triple-negative breast cancer by promoting proliferation and vascular dissemination of cancer cells and the accumulation of intratumoral CD11b+/Gr1+ myeloid cell infiltrates. Overall, our results show how IL30 regulates breast cancer cell viability, migration, and gene expression to promote breast cancer growth and progression and its impact on patient outcome. Cancer Res; 76(21); 6218–29. ©2016 AACR.
Face Mask
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
Authors: Dung T. Le, Johanna C. Bendell, Emiliano Calvo, Joseph W. Kim, Paolo Antonio Ascierto, Padmanee Sharma, Patrick Alexander Ott, Petri Bono, Dirk Jaeger, T.R. Jeffry Evans, Filippo G. De Braud, Ian Chau, Olaf Christensen, Christopher Harbison, Chen-Sheng Lin, Yelena Yuriy Janjigian
Journal: Journal of Clinical Oncology (2016)

6 Background: Patients (pts) with GC/GEC often present with A/M disease, which has a poor prognosis, with 1-year survival &lt; 30%, and few treatment options. Nivolumab is a fully human anti-PD-1 IgG4 monoclonal antibody with a favorable safety profile and efficacy in melanoma, non–small-cell lung cancer, and renal cell carcinoma. The phase I/II, open-label CheckMate-032 study evaluated nivolumab ± ipilimumab in pts with solid tumors. Here, we report initial results for pts with GEC/GC receiving nivolumab monotherapy. Methods: Pts with A/M histologically confirmed GC/GEC, irrespective of PD-L1 status, were assigned to receive nivolumab alone (3 mg/kg IV Q2W) and treated until disease progression (PD) or intolerable toxicity. The primary endpoint was objective response rate (ORR); other endpoints included safety, progression-free survival, overall survival (OS), and biomarker status. Results: 59 pts were enrolled and treated with single-agent nivolumab. Median age was 60 y (range 29–80), and 83% of pts received ≥ 2 prior regimens. At database lock, 10 pts were on active treatment; 49 pts discontinued (PD, n = 40; unrelated adverse events, n = 4; treatment-related adverse events [TRAEs], n = 2; other, n = 3). Pts received a median of 4 doses (range 1–25). ORR was 12% (n = 7/58; 1 complete response, 6 partial responses); 12 pts (21%) had stable disease. Among responders, median duration of response was 7.1 mo (95% CI, 3.0–13.2). Median OS was 6.8 mo (95% CI, 3.3–12.4); 12-mo OS rate was 38% (95% CI, 23.2–52.7). 39% of tumor samples were PD-L1 positive ( ≥ 1% cutoff). ORRs in pts with PD-L1-positive and -negative tumors were 18% and 12%, respectively. TRAEs occurred in 66% of pts; most were Grade 1/2. Grade 3/4 TRAEs occurred in 14% of pts and included pneumonitis, fatigue, diarrhea, vomiting, hypothyroidism, and increased aspartate and alanine aminotransferase and alkaline phosphatase levels. No treatment-related deaths occurred. Conclusions: Nivolumab monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated pts with GC/GEC. Objective responses occurred in pts with PD-L1-positive and -negative tumors. Clinical trial information: NCT01928394.